

Utomilumab (PF-05082566)

Utomilumab (PF-05082566) is an investigational immunotherapy and is a fully human IgG2 monoclonal antibody (mAb).

MECHANISM OF ACTION

The 4-1BB (CD-137) protein receptor is found on certain T cells (primarily on CD8+, but also on CD4+ memory T cells) and natural killer (NK) cells.^{1,2} Based on preclinical data, when utomilumab (PF-05082566) binds to 4-1BB, it has been observed to stimulate and increase the number of immune cells.¹ The hypothesis is that this may help augment enhanced anti-tumor immune function.¹



THE POTENTIAL OF COMBINATION APPROACH

Preclinical studies suggest that combining utomilumab (PF-05082566) with a checkpoint inhibitor, such as anti-PD-1/anti-PD-L1, or other immunotherapies may amplify the immune response.³⁻⁵ Further understanding the biology of how the immune system attacks tumors and ways by which tumors evade the immune system may lead to new investigational approaches.

The safety and efficacy of the agent(s) under investigation have not been established. There is no guarantee that the agent(s) being investigated will receive regulatory approval and become commercially available for use. All information is current as of May 2018.

CONTACT & ADDITIONAL INFORMATION

Pfizer Media Relations Contact

Jessica Smith - Pfizer Oncology Global Media Relations

Phone: 212-733-6213

Mobile: 646-899-3178

Jessica.m.Smith@Pfizer.com

The safety and efficacy of the agent(s) under investigation have not been established. There is no guarantee that the agent(s) being investigated will receive regulatory approval and become commercially available for use. All information is current as of May 2018.

REFERENCES

1. Fisher TS, Kamperschroer C, Oliphant T, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances t-cell function and promotes anti-tumor activity. *Cancer Immunol Immunother*. 2012;61(10):1721-1733.
2. Westwood JA, Hunnam TC, Pegram HJ, et al. Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. *PLoS ONE*. 2014; 9(5):1-10.
3. Gopal A, Barlett N, Levy R, et al. A Phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. *J Clin Oncol*. 2015; 33 (suppl; abstr 3004).
4. Tolcher AW, Szabolc M, Hu-Lieskovan S, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2017; 10.1158/1078-0432.CCR-17-1243.
5. A Study of PF-05082566 as a Single Agent and in Combination with Rituximab. <https://clinicaltrials.gov/ct2/show/NCT01307267?term=PF-05082566&rank=3>. Accessed April 10, 2018.